Avinger Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Avinger şirketinin toplam hissedar öz sermayesi $-1.4M ve toplam borcu $13.8M olup, bu da borç-öz sermaye oranını -1018.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $17.8M ve $19.2M dir.

Anahtar bilgiler

-1,018.8%

Borç/özkaynak oranı

US$13.79m

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.73m
Eşitlik	-US$1.35m
Toplam yükümlülükler	US$19.20m
Toplam varlıklar	US$17.84m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VG20 negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: VG20 şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VG20 negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: VG20 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VG20 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 13 oranında tarihsel oranda büyümeye devam ederse VG20 un bir yıldan az nakit akışı süresi vardır.

Avinger Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

Avinger Regains Compliance with Nasdaq Listing Requirements

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.94 loss in 2Q 2022)

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings released: US$0.71 loss per share (vs US$2.33 loss in 1Q 2022)

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings released: US$0.94 loss per share (vs US$0.73 loss in 2Q 2021)

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.33 loss in 1Q 2021)

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €1.81

Avinger Regains Compliance with Nasdaq Listing Requirements

New 90-day high: €1.36

New 90-day high: €0.44

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Revenue beats expectations

Third quarter 2020 earnings released: US$0.079 loss per share

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - €0.58

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin